Neurons must maintain protein and mitochondrial quality control for optimal function, an energetically expensive process. The peroxisome proliferator-activated receptors (PPARs) are ligand-activated transcription factors that promote mitochondrial biogenesis and oxidative metabolism. We recently determined that transcriptional dysregulation of PPARd contributes to Huntington's disease (HD), a progressive neurodegenerative disorder resulting from a CAG-polyglutamine repeat expansion in the huntingtin gene. We documented that the PPARd agonist KD3010 is an effective therapy for HD in a mouse model. PPARd forms a heterodimer with the retinoid X receptor (RXR), and RXR agonists are capable of promoting PPARd activation. One compound with potent RXR agonist activity is the U.S. Food and Drug Administration-approved drug bexarotene. We tested the therapeutic potential of bexarotene in HD and found that bexarotene was neuroprotective in cellular models of HD, including medium spiny-like neurons generated from induced pluripotent stem cells (iPSCs) derived from patients with HD. To evaluate bexarotene as a treatment for HD, we treated the N171-82Q mouse model with the drug and found that bexarotene improved motor function, reduced neurodegeneration, and increased survival. To determine the basis for PPARd neuroprotection, we evaluated metabolic function and noted markedly impaired oxidative metabolism in HD neurons, which was rescued by bexarotene or KD3010. We examined mitochondrial and protein quality control in cellular models of HD and observed that treatment with a PPARd agonist promoted cellular quality control. By boosting cellular activities that are dysfunctional in HD, PPARd activation may have therapeutic applications in HD and potentially other neurodegenerative diseases.
INTRODUCTION
Huntington's disease (HD) is a progressive autosomal dominant neurodegenerative disorder in which patients develop motor and cognitive impairment (1) . HD pathology is defined by degeneration and death of medium spiny neurons of the striatum, as well as cortical pyramidal neurons that project to the striatum (2, 3) . In 1993, a CAG trinucleotide repeat expansion mutation in the coding region of the huntingtin (htt) gene was identified as the cause of HD (4) . As observed in other polyglutamine (polyQ) repeat diseases, htt glutamine tracts that exceed a certain length threshold (~37 repeats in HD) adopt a new pathogenic confirmation and are resistant to the normal processes of protein turnover, leading to cellular toxicity and neurodegeneration (5) . The length of the mutant htt polyQ expansion inversely correlates with the age of disease onset and rate of disease progression in HD patients.
Neurons in the brain require continued production of high-energy compounds by mitochondria. We and others have linked mitochondrial dysfunction in HD to transcriptional dysregulation of peroxisome proliferator-activated receptor (PPAR) gamma coactivator-1 alpha (PGC-1a), a coactivator that coordinates transcriptional programs that culminate in mitochondrial biogenesis and enhanced oxidative metabolism (6) (7) (8) . The importance of PGC-1a for HD pathogenesis is underscored by the observation that PGC-1a overexpression is sufficient to rescue motor dysfunction, prevent accumulation of misfolded htt protein, and stave off neurodegeneration in HD mice (9) . To determine the mechanistic basis for PGC-1a transcription interference in HD, we performed an unbiased screen that showed PPARs to be htt interactors and documented an interaction between PPARd and htt in non-neuronal cells, striatal-like neurons, and the cerebral cortex of HD mice (10) . We noted that PPARd is highly expressed in neurons of the central nervous system (CNS) and demonstrated that expression of dominantnegative PPARd in CNS is sufficient to produce motor phenotypes, neurodegeneration, mitochondrial defects, and transcriptional abnormalities that closely parallel HD disease phenotypes (10) . We then evaluated a selective, potent PPARd agonist, KD3010, and after confirming that it crosses the blood-brain barrier to up-regulate expression of PPARd target genes in the cortex and striatum, we tested KD3010 in N171-82Q transgenic mice, a rodent model of HD. This study established the efficacy of KD3010 PPARd agonist therapy as a potential therapeutic approach for HD (10) .
One facet of PPARd biology with relevance to therapy development is that PPARd forms a heterodimer with retinoid X receptor (RXR), and the resulting "permissive" PPARd-RXR heterodimer is subject to dual ligand regulation, meaning that RXR agonists can promote PPARd activation (11) . One drug compound with potent RXR agonist activity is bexarotene, a synthetic product structurally similar to retinoic acid compounds, known endogenous RXR ligands. Bexarotene (Targretin) is U.S. Food and Drug Administration-approved for use in patients with T cell cutaneous lymphoma. One provocative study reported that bexarotene administration to a mouse model of Alzheimer's disease (AD) yielded a marked rescue of cognitive, social, and olfactory deficits, accompanied by improved neural circuit function and enhanced clearance of soluble Ab oligomers (12) . The mechanistic basis for this effect was proposed to involve increased PPARg activation (13) . Because PPARd is highly expressed in CNS neurons, more so than PPARg (14) , the mechanistic basis for the therapeutic action of bexarotene in AD deserves reconsideration, in light of our discovery of a role for PPARd in maintaining normal nervous system function (10) and recent work demonstrating the neuroprotective effect of PPARd agonist treatment in AD mice (15) .
Here, we considered the neurotherapeutic potential of bexarotene in HD and found that bexarotene was neuroprotective in multiple cellular models of HD, ranging from mouse striatal and cortical neurons to medium spiny neurons generated from induced pluripotent stem cells (iPSCs) derived from patients with HD. We then treated the N171-82Q HD mouse model with bexarotene and observed improved neuron survival and motor function. To determine the molecular basis for PPARd agonist therapy, we evaluated metabolic dysfunction in HD and documented markedly impaired oxidative metabolism in HD neurons, which was rescued by bexarotene or KD3010. We examined mitochondrial and protein quality control in cellular models of HD and observed that PPARd agonist therapy achieved neuroprotection by promoting quality control function.
RESULTS

Bexarotene promotes PPARd activation resulting in neuroprotection
To evaluate the effect of bexarotene on PPARd activation, we cotransfected PPARd and a 3x-PPAR response element luciferase reporter construct into primary cortical neurons derived from a bacterial artificial chromosome transgenic HD (BAC-HD) mouse model containing the full-length htt gene with 97 glutamine repeats or into primary cortical neurons derived from littermate control [wild-type (WT)] mice. We noted marked induction of PPARd activation upon bexarotene treatment (Fig. 1A) . Bexarotene promotion of PPARd activation was comparable to PPARd activation using a PPARd-selective agonist GW501516 (Fig. 1A) . We also observed a marked increase in PPARd activation when we boosted RXR expression ( fig. S1A ), corroborating the permissive nature of PPARd activation upon heterodimerization with RXR (11) . To determine whether bexarotene-induced PPARd activation countered mutant htt neurotoxicity, we assessed the effect of bexarotene treatment on mitochondrial dysfunction and cell death in BAC-HD neurons. When we measured mitochondrial membrane potential using two different fluorescent probes, we noted significantly reduced mitochondrial membrane potential in BAC-HD neurons, which was rescued upon bexarotene treatment (Fig. 1B and fig. S1B ). Similarly, bexarotene treatment yielded a significant reduction in the frequency of BAC-HD neurons that displayed caspase-3 activation, an indicator of impending cellular demise (Fig. 1C) . Previous studies of bexarotene neuroprotection in an AD mouse model have proposed that bexarotene neuroprotection relies upon activation of PPARg (12) .
To determine the basis for bexarotene neuroprotection in HD neurons, we repeated bexarotene treatment of BAC-HD primary neurons along with concurrent knockdown of either PPARa, PPARd, or PPARg, which was accomplished by coexpression of short hairpin RNA (shRNA) vectors directed against each of the different PPARs ( fig.  S1C ). When we measured mitochondrial membrane potential in BAC-HD neurons treated with bexarotene and subjected to knockdown of either PPARa, PPARd, or PPARg, we found that bexarotene rescue of mitochondrial membrane potential occurred despite PPARa or PPARg knockdown but was prevented by concurrent knockdown of PPARd (Fig. 1D) . Bexarotene neuroprotection was not limited to BAC-HD primary cortical neurons because bexarotene treatment also improved mitochondrial function and cell survival of WT neurons; enhanced WT neuron function upon exposure to bexarotene also depended upon PPARd (fig. S1, D and E). We then assayed bexarotene rescue of BAC-HD neuronal cell death and noted that PPARd knockdown eliminated any benefit from bexarotene treatment, whereas PPARa or PPARg knockdown did not significantly affect bexarotene neuroprotection (Fig. 1E) . Finally, to determine whether bexarotene treatment of BAC-HD primary neurons promoted increased PPARd activation, we measured the RNA expression of PPARd targets previously shown to respond to PPARd agonist treatment pharmacodynamically in mice (10) . We documented bexarotene-induced expression of these PPARd target genes (Fig. 1F) . We noted that combined bexarotene + GW501516 treatment often yielded even greater increases in PPARd target gene expression (Fig. 1F) .
To further evaluate bexarotene neuroprotection in HD, we pursued experiments in different models of mutant htt neurotoxicity that aim to recapitulate HD neuropathology. First, we transfected cocultured mouse cortical and striatal neurons with N-terminal htt containing 90 amino acids with either an 8-glutamine repeat (Nt-90-8Q) or a 73-glutamine repeat expansion (Nt-90-73Q) and treated cocultured cortical and striatal neurons with increasing bexarotene concentrations. We observed a significant increase (P < 0.05 or P < 0.01) in neuron survival in a dose-dependent manner (Fig. 2, A and B) . We then tested the effect of bexarotene in primary cortical neurons transfected with N-terminal htt containing 586 amino acids with an 82-glutamine repeat expansion (Nt-586-82Q) and noted a dose-dependent reduction (P < 0.01 or P < 0.001) in neuronal cell death (Fig. 2C) . We also differentiated human HD iPSCs into striatal medium spiny-like neurons and transferred them to brain-derived neurotrophic factor (BDNF)-free neural induction medium because withdrawal of neurotrophic factor support promoted neuronal cell death. To evaluate rescue, we supplemented the media with either bexarotene or BDNF, which robustly prevented neuronal cell death in this system. We observed marked protection of HD medium spiny-like neurons from cell death upon either bexarotene or BDNF treatment (Fig. 2D) . These findings indicate that bexarotene can ameliorate mutant htt neurotoxicity.
Bexarotene treatment improves motor function and rescues neurodegeneration in HD mice Because bexarotene displayed neuroprotection against mutant htt toxicity and is already approved for use in humans, we investigated bexarotene treatment in N171-82Q mice, which recapitulate HD-like motor phenotypes and neurodegeneration within a time frame of 5 to 6 months (16) . Bexarotene is a lipophilic molecule that readily crosses the blood-brain barrier in rodents (17, 18) . To establish the dosage for a preclinical trial, we performed a pharmacodynamics study by delivering bexarotene via intraperitoneal injection, at either 10 or 30 mg/kg for 3 days/week for 1 week, to 6-week-old WT C57BL/6J mice and then measuring PPARd target gene expression in the striatum. We observed comparable increases in PPARd target gene expression in the brains of mice on the dosage regimen (10 mg/kg) and the dosage regimen (30 mg/kg) ( fig. S2 ). However, we noted that the bexarotene dosage regimen (30 mg/kg) was not well tolerated, causing significant morbidity. The bexarotene dosage (10 mg/kg) regimen did not cause weight loss or visible side effects based on a neurological screening exam, nor did we detect any evidence of organ toxicity at necropsy.
Next, we injected N171-82Q mice with either bexarotene or vehicle (10 mg/kg per day), three times per week, beginning at 6 weeks of age. We adhered to recommended preclinical trial guidelines, intended to avoid spurious results (19, 20) . We tracked the progression of disease phenotypes in vehicle-and bexarotene-treated HD mice by performing a composite neurological examination (21) and rotarod analysis at monthly intervals. Bexarotene treatment rescued neurological dysfunction and improved motor function in HD mice, as compared to vehicle-treated HD mice (Fig. 3, A and B, and fig. S3 , A to D). Bexarotene also extended life span in HD mice by an average of 9.8 days (Fig. 3C) . Neuropathology analysis further indicated that bexarotene treatment yielded a reduction in htt protein aggregates and prevented neuronal cell loss in the striatum of HD mice (Fig. 3, D 
to F).
Bexarotene rescues PPARd target gene expression in both CNS and skeletal muscle of HD mice To confirm that bexarotene treatment elicited induction of PPARd activation in HD mice, we measured the expression of the PPARd target genes angiopoietin-like 4 (Angptl4) and uncoupling protein 2 (Ucp2) in the cortex and striatum of bexarotenetreated mice and documented marked increases in Angptl4 and Ucp2 expression in comparison to vehicle-treated HD mice (Fig. 4 , A and B). In human patients, sampling of CNS tissues was not feasible. Because PPARd is highly expressed in skeletal muscle, a practical alternative strategy would be to measure PPARd target gene expression in this highly accessible tissue in the HD mice. We thus assayed the expression of five PPARd target genes, Ucp2, adipose differentiationrelated protein (Adfp), lipoprotein lipase (Lpl), pyruvate dehydrogenase kinase isoform 4 (PDK4), and stearoyl-coenzyme A desaturase 1 (Scd1), in quadriceps muscle samples obtained from WT controls and bexarotene-and vehicle-treated HD mice. For all tested PPARd target genes except Lpl, we observed rescue of gene expression; for Pdk4 and Scd1, we noted marked up-regulation of expression at three-to fivefold that of WT HD mice (Fig. 4C ).
To assess the rapidity of productive PPARd target engagement in mouse skeletal muscle, we assembled two additional cohorts of HD N171-82Q mice, and we treated one HD cohort with vehicle and the other HD cohort with bexarotene at 10 mg/kg for 1 week. Induction of PPARd target gene expression in quadriceps muscle was detected for three of the five targets in HD mice treated with bexarotene for just 1 week ( fig. S4 ). These results indicate that PPARd target gene expression in mouse skeletal muscle could serve as a marker of response to PPARd agonist treatment.
PPARd agonist treatment restores oxidative metabolic function in HD mice
Our bexarotene preclinical trial in HD mice, together with a recent preclinical trial of the PPARd agonist KD3010 (10), suggests that PPARd agonists may be a potential treatment for HD. How does PPARd agonist treatment achieve in vivo neuroprotection? PPARd has been shown to improve bioenergetics function by promoting mitochondrial adenosine triphosphate (ATP) generation in skeletal muscle (22, 23) . Mitochondrial dysfunction is a key feature of HD pathogenesis (24) . To determine whether PPARd agonist treatment affected mitochondrial function in HD, we performed a bioenergetics profile of HD mouse primary Total numbers counted for fluorescently transfected neurons for each condition were normalized to Htt Nt-90-8Q-transfected neurons at baseline, with neuron survival arbitrarily set to 1. *P < 0.05, **P < 0.01, Student's t test. n = 3 independent experiments. (B) We measured survival of striatal neurons in cortical neuron-striatal neuron cocultures transfected with the indicated Htt expression vector and treated with bexarotene at the indicated concentration. Total numbers counted for fluorescently transfected neurons for each condition were normalized to Htt Nt-90-8Q-transfected neurons at baseline, with survival arbitrarily set to 1. *P < 0.05, **P < 0.01, Student's t test. n = 3 independent experiments. (C) We quantified cell death in mouse primary cortical neurons, transfected with the indicated Htt expression vector, and treated with vehicle or bexarotene at the indicated concentration. **P < 0.01, ***P < 0.001, Student's t test. n = 6 independent experiments. (D) We quantified cell death in medium spiny-like neurons differentiated from an induced pluripotent stem cell line derived from a patient with HD carrying a 60Q allele in the huntingtin gene and treated with bexarotene (1.0 mM) or brain-derived neurotrophic factor (BDNF; 20 ng/ml). *P < 0.05, **P <0.01, Student's t test. n = 3 independent experiments. Error bars represent SEM.
cortical neurons in comparison to WT mouse primary cortical neurons and evaluated the effects of bexarotene and KD3010. Extracellular flux analysis revealed that HD mouse neurons displayed a markedly reduced oxygen consumption rate (OCR) at baseline compared to WT neurons and that the spare respiratory capacity of HD neurons, reflected by the maximal OCR, was also markedly reduced in comparison to WT neurons (Fig. 5A) . Because PPARg was shown to drive ATP generation through mitochondrial oxidation of fatty acids (25), we supplied WT and HD mouse primary cortical neurons with palmitate, but this substrate did not produce any further differences in oxidative metabolism between WT and HD neurons. Treatment with bexarotene or KD3010 yielded a marked improvement in both basal OCR and maximal OCR in HD neurons (Fig. 5 , A to C), restoring OCR to that of WT neurons. In addition to measuring OCR, we also recorded rates of glycolysis by assaying the extracellular acidification rate (ECAR) and confirmed that HD neurons produce ATP primarily via glycolysis but that bexarotene or KD3010 treatment reverts HD neurons to an oxidative mode of energy production (Fig. 5D ). Given the potency of PPARd agonist treatment for boosting oxidative metabolism in HD neurons, we measured the effect of bexarotene or KD3010 treatment on WT neurons and noted significant increases in basal OCR (P < 0.01) and maximal OCR (P < 0.05) ( fig. S5A ), indicating that PPARd activation is also capable of boosting bioenergetics function in WT neurons. To determine the relevance of this bioenergetics profile of HD primary neurons to the effects of bexarotene treatment in vivo, we performed quantitative reverse transcription polymerase chain reaction (RT-PCR) analysis on striatal RNAs for subsets of PPARd target genes whose protein products function in the oxidative phosphorylation, glycolysis, or gluconeogenesis pathways. We documented restoration of a gene expression pattern matching the WT oxidative profile for bexarotene-treated mice (Fig. 5E ). When we extended this analysis to skeletal muscle from bexarotene-and KD3010-treated HD mice, we observed a similar phenomenon ( fig. S5B ).
PPARd improves mitochondrial and protein quality control to achieve neuroprotection Neurons are placed under a constant demand for energy and are in a continuous battle to maintain mitochondrial quality control and protein quality control. Decompensation of proteostasis and mitochondrial quality control are defining features of neurodegenerative diseases, including HD (24, 26) . Because quality control processes are extremely energy intensive, and PGC-1a genetic rescue prevents protein aggregation and boosts mitochondrial function (9), we reasoned that PPARd agonist treatment may ameliorate defects in mitochondrial quality control and protein quality control through its rescue of metabolic function. To test this hypothesis, we examined the mitochondrial morphology of striatal-like neurons carrying homozygous CAG-111 repeat expansion mutations in the mouse htt gene (ST-Hdh Q111/Q111) (27) . Comparison of ST-Hdh Q111/Q111 cells with control ST-Hdh Q7/Q7 cells revealed an increase in mitochondrial fragmentation in Q111/Q111 cells (Fig. 6, A and B) . Bexarotene treatment of ST-Hdh Q111/ Q111 striatal-like cells yielded a significant reduction (P < 0.05 or P < 0.01) in mitochondrial fragmentation in a dosedependent fashion (Fig. 6B) . Because PPARd agonist treatment boosted metabolic function in normal neurons ( fig.  S4A) , we tested the effect of PPARd activation on ST-Hdh Q7/Q7 cells and observed an increase in mitochondrial length; we detected a reduction in mitochondrial length upon PPARd knockdown (Fig. 6C ).
Oxidative stress impairs mitochondrial quality control, promoting fragmentation (28). When we treated ST-Hdh Q7/Q7 striatal-like cells with hydrogen peroxide, we observed a marked reduction in mitochondrial length, and this mitochondrial length reduction could be ameliorated by combined PPARd overexpression and bexarotene treatment (Fig. 6D) . Similarly, hydrogen peroxide yielded markedly greater mitochondrial fragmentation in ST-Hdh Q111/Q111 striatal-like cells, which was rescued by combined PPARd overexpression and bexarotene agonist treatment (Fig. 6E) . To assess the in vivo relevance of these findings, we quantified mitochondrial genomic DNA (mitoDNA) and nuclear genomic DNA (nDNA) in the striatum of bexarotene-treated HD mice. We documented an increase in the mitoDNA/ nDNA ratio, which is an index of the abundance of mitochondrial biomass, in HD mice treated with bexarotene (Fig. 6F) .
To determine whether PPARd activation status affects protein quality control, we used a Neuro2a cell culture model of mutant htt aggregation, where transfection of N-terminal htt protein with 104 glutamine repeats yields marked aggregate formation in Neuro2a cells subjected to oxidative stress (9) . Using this system, we found that treatment with the PPARd agonist GW501516 or bexarotene elicited a marked reduction in htt-Q104 protein aggregation (Fig. 7A ) and confirmed that bexarotene-mediated turnover of mutant htt protein was RXR-dependent ( fig. S6 ). To establish which arm of the proteostasis pathway was responsible for the bexarotene-mediated reduction in htt aggregation, we performed htt-104Q transfection of Neuro2a cells in the presence of bexarotene, in combination with either lactacystin or spautin-1. We found that spautin-1 inhibition of autophagy blunted the reduction of htt aggregation achieved with bexarotene treatment, but lactacystin, an inhibitor of the ubiquitin-proteasome system, had no significant effect (Fig. 7B) . Knockdown of the autophagy-related 7 (Atg7) gene similarly yielded a significant blunting of bexarotene-mediated htt aggregate rescue in this system (Fig. 7B ). To directly evaluate the effect of PPARd activation on autophagy, we assayed autophagy flux in Neuro2a cells subjected to PPARd shRNA knockdown or PPARd agonist activation and noted a reduction in autophagy flux upon PPARd knockdown and a significant increase in autophagy flux with PPARd agonist activation (Fig. 7C ). This increase in autophagy flux could also be achieved with bexarotene activation of RXR (Fig. 7D) . Transcription factor EB (TFEB) is a master regulator of autophagy (29) , and upon PGC-1a induction, TFEB expression increases, thereby promoting autophagy (9) . To assess the role of TFEB in PPARd activation of autophagy, we measured autophagy flux in HeLa cells deficient in TFEB (fig. S7, A and B) . We detected an increase in autophagy flux upon PPARd agonist treatment that was comparable to the increased autophagy flux observed in WT HeLa cells treated with a PPARd agonist ( fig. S7, C and D) , thereby ruling out a role for TFEB in PPARd-mediated autophagy activation. To determine whether bexarotene amelioration of mutant htt protein aggregation depended upon PPARd activation, we quantified htt-Q104 aggregation in Neuro2a cells treated with bexarotene in the presence or absence of a specific PPARd inhibitor (GSK3787) and noted that PPARd inhibition abrogated bexarotene amelioration of htt protein aggregation (Fig. 7E) . These findings indicate that PPARd activation achieves neuroprotection by improving mitochondrial and protein quality control pathways. dysfunction and impaired protein-organelle quality control. We and others previously linked mitochondrial dysfunction and transcriptional dysregulation in HD to interference with the transcription coactivator PGC-1a (6, 8, 30) . Because mutant htt does not directly interact with PGC-1a to blunt its function, we pursued the mechanistic basis for this transcription interference and identified the nuclear hormone receptor PPARd as a direct target of mutant htt neurotoxicity (10) . Because PPARd heterodimerizes with RXR to activate its target genes, and the resulting permissive PPARd-RXR heterodimer is subject to dual ligand regulation, RXR agonists are capable of promoting PPARd activation (11) . Here, we examined bexarotene in various in vitro cellular models of HD and observed robust neuroprotection, suggesting the neurotherapeutic potential of bexarotene in HD. We investigated bexarotene treatment in HD N171-82Q mice using a study design that adhered to guidelines for rigor and reproducibility (19, 20) . We documented improvements in motor function, htt protein aggregation, striatal neurodegeneration, and mouse survival. Bexarotene (also called Targretin) is approved for use in humans for T cell cutaneous lymphoma but is also currently in clinical trials in AD patients based on previous preclinical trial work in an AD mouse model (12) . The mechanistic basis for the therapeutic efficacy of bexarotene was proposed to be increased activation of PPARg, supporting a presumed role for enhanced Ab clearance by PPARg-expressing microglia (13) . Because PPARd is highly expressed in CNS neurons (14) , and bexarotene can also potently activate PPARd, we sought the basis for bexarotenemediated neuroprotection in BAC-HD primary neurons by concurrently knocking down the expression of PPARa, PPARd, or PPARg. For all tested readouts, we found that PPARd is required for amelioration of mutant htt neurotoxicity. Our findings thus suggested that bexarotene neuroprotection involved PPARd activation and that enhanced PPARd activation could be contributing to the beneficial effects of bexarotene in AD (12, 31) . Although bexarotene readily crosses the blood-brain barrier in rodents (17, 18) , it does not efficiently cross the blood-brain barrier in healthy human subjects (32) , implying that bexarotene therapeutic responses observed in neurodegenerative disease patients may stem from the peripheral benefits of RXR and PPARd activation or from alteration of blood-brain barrier function in human patients (33) . An important question that we sought to answer in this investigation was how PPARd achieved neuroprotection. Numerous studies have examined the role of PPARd in skeletal muscle, and these efforts led to the realization that PPARd strongly favors oxidative metabolism, resulting in an increase in ATP (22, 23) . Increased PPARd activation in skeletal muscle is sufficient to yield profound changes in muscle physiology and endurance exercise performance. These changes have been linked to altered gene expression that enhances the function of the tricarboxylic acid cycle and oxidative phosphorylation pathway (22, 23) , preservation of glucose concentrations (34) , and boosting of PGC-1a (35) . We recently surveyed the expression of the PPARs and found that only PPARd is highly expressed in CNS neurons (10) . We further found that transgenic expression of a dominant-negative PPARd mutant in mice resulted in marked neurodegeneration in the context of diminished electron transport chain activity and greatly reduced ATP (10). We therefore directly assayed metabolic function by performing extracellular flux analysis on cortical neurons from BAC-HD mice and observed marked reductions in OCR. These metabolic defects were reversed when we treated HD neurons with bexarotene or the PPARd agonist KD3010, indicating that PPARd agonist therapy, whether achieved with a PPARd agonist or RXR agonist, is capable of reverting HD neurons from glycolytic metabolism to oxidative metabolism.
Neurons are unique because they are postmitotic, have high energy requirements, and are exquisitely vulnerable to misfolded protein stress and defects in organelle quality control. Misfolded proteins, or peptide fragments thereof, are a defining feature of neurodegenerative disorders, including HD, PD, and AD (36) . Neurons thus require energy not only for synaptic neurotransmission and transport of materials back and forth along their dendrites and axons but also for maintaining protein and organelle quality control. We reasoned that impaired oxidative metabolism in HD likely deprives neurons of the energy required to maintain mitochondrial quality control and proteostasis, especially given that altered mitochondrial dynamics and proteostasis are well-established characteristics of HD pathology. Evidence from patient material, cell culture models, and BAC-HD mice indicates that HD neurons contain highly fragmented mitochondria (37) (38) (39) . Because excessive mitochondrial fission occurs in HD, likely because of altered regulation of the fission regulatory proteins Drp1 and Fis1 (38, 40, 41) , dysregulation of mitochondrial dynamics in HD implies that maintenance of normal mitochondrial morphology in HD requires an even greater expenditure of energy. Support for this view comes from ultrastructural analysis of mice that recapitulate HD phenotypes upon expressing dominantnegative PPARd in striatal neurons, whose mitochondria appear highly fragmented (10) . After confirming that excessive mitochondrial fragmentation occurs in ST-Hdh Q111/Q111 mouse striatal-like cells, we treated Q111/Q111 cells with bexarotene and observed reductions in mitochondrial fragmentation. We further found that improved energy production can counter mitochondrial fragmentation induced by oxidative stress in normal striatal-like cells, suggesting that PPARd activation may be capable of supporting mitochondrial quality control in different stress situations.
In our bexarotene HD mouse study and in a previous study of PGC1a overexpression (9) , these interventions yielded reductions in htt protein aggregation in the brains of HD mice. To determine how bexarotene activation of PPARd promotes proteostasis, we tested the effect of proteasome inhibition or autophagy inhibition on the bexarotene-mediated reduction of htt aggregates and found that autophagy inhibition sharply countered htt aggregate reduction in bexarotenetreated cells. We documented markedly increased autophagy flux when we transfected cells with PPARd in the presence of an agonist but noted diminished autophagy flux when we performed PPARd knockdown. Hence, our results indicate that PPARd activation can up-regulate autophagy. This finding agrees with previous work where PPARd agonist treatment of cardiomyocytes yielded increased light chain 3 (LC3)-II, suggestive of autophagy induction, and where an analysis of PPARd knockout mice revealed reductions in autophagy markers in the heart (42) . Because PGC-1a can promote increased expression of TFEB (9), a master regulator of autophagy, we evaluated the effect of PPARd modulation in TFEB knockout cells and observed that PPARd activation yielded increased autophagy flux in the absence of TFEB, indicating that PPARd up-regulation of autophagy is not TFEB-dependent.
A frequent observation in neurodegenerative diseases is the failure of mitochondrial energy production to keep up with CNS demand for ATP, coupled with an inability to maintain protein quality control and organellar homeostasis. Energy production and quality control function are inextricably linked because neurons require energy for proteostasis and organelle quality control, and protein and organelle quality control must operate efficiently if a neuron is to retain a complement of fully functional mitochondria to carry out the task of ATP generation. If one arm of this homeostasis loop is disrupted, the other arm of the loop will inevitably become dysfunctional, and worsening dyshomeostasis will ensue because the altered process will act as a positive feedback loop. In HD, we and others have discovered a central role for impaired mitochondrial energy production and quality control (6, 9, 30) , and we have homed in on PPARd as a regulatory factor capable of promoting oxidative metabolism to yield energy. Because energy is necessary for promoting mitochondrial quality control at the level of mitochondrial dynamics, we tested whether PPARd activation could rescue mitochondrial fragmentation in HD and found that PPARd activation prevented mitochondrial fragmentation in HD cells. In HD, as in other neurodegenerative diseases, there is selective vulnerability of certain types of neurons. In the case of HD, it is striatal medium spiny neurons that are preferentially lost. Although the basis for this selective vulnerability is unknown, certain studies have found that striatal neurons are prone to mitochondrial fragmentation due to increased expression of the Drp1 receptor Fis1 (43), a pro-fission effect of dopaminergic signaling (40) , or increased S-nitrosylation of Drp-1 (41) . Thus, in HD, the energy demands of medium spiny neurons, together with a predisposition to fragmentation of the mitochondrial network, may explain why PPARd transcription interference contributes to HD pathogenesis and why PPARd promotion of mitochondrial fusion in HD is neuroprotective.
Here, we considered an alternate approach for PPARd activation based on its formation of permissive heterodimers with RXR and found that bexarotene treatment counters mutant htt toxicity both in vitro and in vivo in HD. Our findings thus indicate that bexarotene deserves consideration as a potential therapy for HD. However, because this study only evaluated bexarotene in an HD mouse model featuring expression of truncated protein, further study of bexarotene in an HD mouse model featuring expression of full-length htt protein is warranted. Furthermore, although HD mouse models recapitulate many aspects of the human disease, their predictive value for gauging the potential utility of a therapeutic intervention remains uncertain. Performing parallel studies in cell culture, mouse primary neurons, and human stem cell models is necessary to corroborate evidence for an agent's neuroprotection. Although this strategy was used here, it is important to recognize that these systems also have their limitations. Although bexarotene is approved for use in humans, its use is associated with side effects that can be dose-limiting (44) . We have previously shown that the PPARd agonist KD3010 is capable of robust neuroprotection in HD (10) . Although KD3010 was found to be safe in humans in a phase 1b clinical trial, its dosage range for chronic, long-term use has yet to be established. Because bexarotene and KD3010 act on different transcription factors, one appealing approach would be to use combinatorial therapy in which the dosages of each compound could be reduced to limit their respective side effects while achieving an additive or perhaps even synergistic treatment response in HD patients.
MATERIALS AND METHODS
Study design
The primary objective of this study was to determine whether the RXR agonist bexarotene was an effective treatment for HD. Bexarotene was evaluated in primary mouse neurons and human patient stem cellderived neurons in experiments that used quantitative real-time PCR and assays of mitochondrial function and cell death. Bexarotene was tested in a preclinical trial in a mouse model of HD, with motor function, neuropathology, and survival as the outcome measures. The preclinical trial, which was approved by and performed in accordance with the University of California, San Diego (UCSD) Institutional Animal Care and Use Committee (IACUC), adhered to a protocol where we arbitrarily divided littermates and balanced genders between experimental groups, with behavioral testing performed by investigators blinded to the treatment group of the mice. We based our group sizes on power analysis to achieve 80% likelihood of detection of a 30% rescue of motor phenotypes. In the second half of this study, we sought the mechanisms by which PPARd agonists achieved neuroprotection in our HD mouse model using experiments that used quantitative real-time PCR, in vitro assays, immunohistochemistry, and Western blotting. For all experiments, replicate numbers are stated in the figure legends.
Cell culture and primary neuron studies ST-Hdh cells were cultured as described previously (45) . Primary cortical neurons from BAC-HD and WT mice were prepared as described previously (10, 46) . Cotransfection with indicated constructs [as described previously (10) ] was done with Lipofectamine 3000 as per the manufacturer's protocol (Invitrogen). Lentiviral transduction was used to induce gene expression or knockdown in primary neurons, with infection achieved by adding 1 × 10 7 titer units of lentivirus to the culture media. For reporter assays, cells were drug-treated 24 hours after reporter transfection, harvested 24 hours later, and subjected to analysis using the Dual-Luciferase Reporter Assay System (Promega). Mitochondrial membrane potential was measured via live cell loading with a potential-sensitive dye, either JC-1 or tetramethylrhodamine methyl ester (TMRM), using the Tecan M200 PRO Reader. JC-1 was used for preliminary tests, followed by more extensive mitochondrial characterization by Seahorse metabolism analysis. Analysis of cell death with immunofluorescence to activated caspase-3 was performed as described (47) . H 2 O 2 treatment was 25 mM for 4 hours. Glucose starvation was done for 2 hours in Dulbecco's modified Eagle's medium without glucose and 10% dialyzed fetal bovine serum. Treatments with PPARd antagonist GSK3787 (GSK), lactacystin (L6785, SigmaAldrich), spautin-1 (SML0440, Sigma-Aldrich), and bafilomycin A1 (B1793, Sigma-Aldrich) were as indicated for individual experiments. In all experiments, the investigator was blinded to culture conditions and cell treatments.
Primary mouse cortical neurons were prepared from CD1 mice as described previously (48) . Cotransfection was performed at days in vitro 5 with the N586 fragment of Htt containing either 22Q (N586-Htt 22Q) or 82Q (N586-Htt 82Q) and enhanced green fluorescent protein (GFP) (10:1 ratio) with Lipofectamine 2000 according to the manufacturer's protocol. Bexarotene treatment (1 mM) was done at the time of transfection. After 48 hours of expression, cells were fixed with 4% paraformaldehyde (PFA) for 30 min, and nuclei were stained with Hoechst 33258 (bis-benzimide, Sigma-Aldrich). Image acquisition was done using the AxioVision imaging software on an Axiovert 100 inverted microscope (Carl Zeiss). Analysis and quantification were performed using Volocity (PerkinElmer). Nuclear staining intensity of GFP-positive cells was measured, and neurons with a nuclear intensity of up to 200% of the intensity of healthy control were considered viable.
Primary rat cortical and striatal neurons were isolated from E18 Sprague-Dawley rat brains as described previously (49) . Briefly, Nt-90-8Q and Nt-90-73Q constructs were transfected into separately isolated cortical and striatal neurons using electroporation. Cortical and striatal neurons were also cotransfected with yellow fluorescent protein (YFP) or mCherry, respectively, as separate viability markers, and then cocultured on previously established glial cell beds for 5 days before automated counting of YFP or mCherry neurons (49) . Total numbers counted for fluorescently transfected neurons for each condition were normalized to Htt Nt-90-8Q-transfected neurons at baseline, with survival arbitrarily set to 1.
Animal studies and preclinical trial All animal experimentation adhered to National Institutes of Health (NIH) guidelines and was approved by and performed in accordance with the UCSD IACUC. Cohort sizes were designated on the basis of power analysis for threshold effects of at least 25% difference. After genotyping, we performed motor baseline assessment before group assignments and divided littermates and balanced genders between experimental groups, in accordance with guidelines intended to avoid spurious results (19, 20) . After group assignment, we initiated MondayWednesday-Friday intraperitoneal injections of bexarotene (10 mg/kg per day) as a suspension in corn oil (3 mg/ml) at 6 weeks of age. Blinded observers visually inspected mice for obvious neurological signs, examined mice with a composite neurological evaluation tool as described previously (21) , and also examined motor phenotypes by performing rotarod testing as described previously (10) . For neuropathology experiments, brains were harvested, and histopathology, volume measurements, and stereology analysis were performed as described previously (10) . In all cases, the scorer was blinded to the genotype status and treatment condition of the mice.
Real-time RT-PCR analysis RNA samples were isolated using TRIzol (Life Technologies). Genomic DNA was removed using RNase-free DNase (Ambion). mRNA quantification was performed using the 7500 Real-Time PCR System (Applied Biosystems) with Applied Biosystems Assays-on-Demand primers and TaqMan-based probes (50) or using the SYBR Green system (51) . Applied Biosystems TaqMan primer and probe set designations are available upon request. 18S or b-actin RNA was used as internal controls. Relative expression levels were calculated via the DDC t method.
Western blot analysis
Proteins were run on 10% bis-tris gels (Invitrogen) and transferred to polyvinylidene difluoride membranes (Millipore) before blocking in Odyssey Blocking Buffer (LI-COR Biosciences). Membranes were incubated with antibodies as indicated: LC3 (NB100-2220, Fisher); TFEB (4240S, Cell Signaling), p-S6K (9234, Cell Signaling), and p-S6 (2215, Cell Signaling); or b-actin (ab8226, Abcam); and imaged on the Odyssey System (LI-COR Biosciences).
Mitochondrial studies
The OCR and ECAR of primary neurons grown in Seahorse plates were measured using an Extracellular Flux Analyzer (Seahorse Bioscience), following the manufacturer's instructions. The Seahorse values were normalized by protein mass, which was determined by bicinchoninic acid protein assay (Thermo Fisher Scientific) after the measurement.
ST-Hdh cells were transfected with the indicated constructs [as previously described (10) ] with Lipofectamine 3000 as per the manufacturer's protocol (Invitrogen) and treated with compounds as indicated: H 2 O 2 (25 mM, 4 hours); GW501516 was at 100 nM for 24 hours. Cells were fixed with 4% PFA and stained for translocase of outer mitochondrial membrane 20 (TOM20) to delineate mitochondria. Cells were imaged at 63× on a Zeiss 780 confocal microscope. Images were analyzed with the NIH ImageJ program using a written script from Dickey and Strack (52) .
Statistical analysis
All data were prepared for analysis with a standard spreadsheet software (Microsoft Excel). Statistical analysis was done using Microsoft Excel, Prism 4.0 (GraphPad), or the VassarStats website (http://vassarstats. net/). For analysis of variance (ANOVA), if statistical significance (P < 0.05) was achieved, we performed post hoc analysis to account for multiple comparisons. All t tests were two-tailed unless otherwise indicated, and the level of significance (a) was always set at 0.05.
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